key: cord-0979317-9cv75g3b authors: Takakuwa, Teruhito; Nakagama, Yu; Yasugi, Mayo; Maeda, Toshiki; Matsuo, Kenji; Kiritoshi, Ayako; Deguchi, Ryo; Hagawa, Naohiro; Shibata, Wataru; Oshima, Kazuhiro; Yamamoto, Katsumi; Uchida, Kenichiro; Noda, Tomohiro; Yamada, Koichi; Nishimura, Tetsuro; Yamamoto, Hiromasa; Kido, Yasutoshi; Hino, Masayuki; Kakeya, Hiroshi; Mizobata, Yasumitsu title: Discrepant Antigen-specific Antibody Responses Causing SARS-CoV-2 Persistence in a Patient Receiving B-cell-targeted Therapy with Rituximab date: 2021-12-01 journal: Intern Med DOI: 10.2169/internalmedicine.7884-21 sha: 5e94a225ad7160efbeb95472603f6fbfbf87e702 doc_id: 979317 cord_uid: 9cv75g3b A 73-year-old man previously treated with rituximab for his mucosa-associated lymphoid tissue lymphoma suffered a suboptimal humoral immune response against an acquired SARS-CoV-2 infection. A detailed serological description revealed discrepant antigen-specific humoral immune responses. The titer of spike-targeting, “viral-neutralizing” antibodies remained below the detection level, in contrast to the anti-nucleocapsid, “binding” antibody response, which was comparable in both magnitude and kinetics. Accordingly, viral neutralizability and clearance was delayed, leading to prolonged RNAemia and persistent pneumonia. The present case highlights the need to closely monitor this unique population of recipients of B-cell-targeted therapies for their neutralizing antibody responses against SARS-CoV-2. Increased death rates for the novel coronavirus infection (COVID-19) have been reported in patients with hematologic malignancies compared with the general population (1). Whether or not patients receiving B-cell-targeted therapies for their underlying malignancy can successfully develop SARS-CoV-2 specific antibodies (2) (3) (4) , which are essential for achieving viral clearance and preventing future reinfections, is now of increasing concern. Furthermore, with the first generation of COVID-19 vaccines now being delivered, the vaccine response of subjects receiving anti-CD 20-depleting therapy is the next issue to be addressed for the appropriate individualization of vaccination schedules (5) . We herein report a patient previously treated with B-celltargeted, anti-CD20 monoclonal antibody therapy for mucosa-associated lymphoid tissue (MALT) lymphoma who suffered a suboptimal humoral immune response, resulting in SARS-CoV-2 dissemination and uniquely persistent COVID-19 pneumonia. Our detailed antigen-specific serological description highlights the need to closely monitor this particular vulnerable population for their neutralizing anti-spike antibody response, both after successful recovery and after vaccine administration. A 73-year-old man was diagnosed with esophageal MALT lymphoma by an upper gastrointestinal endoscopic needle biopsy. With metastases and bone marrow involvement ruled out, the patient was determined to have stage I disease. Following eight doses of anti-CD20-depleting rituximab therapy, localized irradiation was administered after observing residual positron emission tomography activity in the primary lesion. Twelve weeks after receiving his last dose of rituximab, the patient developed a fever and respiratory symptoms. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) testing performed on the fourth day of illness was positive for SARS-CoV-2. Not only respiratory specimens but also his serum was positive for SARS-CoV-2, indicating the presence of RNAemia resulting from SARS-CoV-2 dissemination. Chest computed tomography (CT) findings were significant for ground-glass opacities in the right upper lobe and atelectases/infiltrations in both dorsal lower lung fields ( Fig. 1) , indicative of a COVID-19 type H phenotype. Laboratory examinations showed lymphopenia (0.39×10 9 cells/L), and a flow cytometric analysis revealed complete depletion of CD19-positive circulating B cells. The patient's severe respiratory distress required management with mechanical ventilation. A combination of favipiravir (2 loading doses of 1,800 mg followed by 800 mg twice daily) and chloroquine (400 mg per day) was initiated but showed no apparent efficacy. High-dose methylprednisolone slightly improved his ventilation parameters, such as the PaO2/FiO2 ratio, but only in a transient manner. Additional treatment with a single dose of ivermectin (15 mg) was carried out. Sputum specimen RT-PCR performed on day 24 of illness remained positive for SARS-CoV-2. The extraordinarily delayed viral clearance prompted detailed analyses of his serological status, in order to gain insight into the pathophysiology of the persistent COVID-19 infection in this patient. SARS-CoV-2 specific antibody testing of the serum sample obtained after 25 days from the on-set showed discrepant results; Architect SARS-CoV-2 IgG (Abbott Laboratories, Chicago, United States) targeting the nucleocapsid antigen showed an elevated titer, while a SARS-CoV-2 IgG Quantum Dot Immunoassay (Mokobio Biotechnology R&D center, Rockville, United States) targeting the spike-antigen detected no significant signal ( Fig. 2A) . Accordingly, as antibodies targeting the spike antigen receptor-binding domain are used to determine viral neutralizability (6, 7) , the in vitro viral neutralization assay confirmed that the patient's serum showed negligible viral neutralizability ( Fig. 2A) . A time-course serial sample analysis revealed that the patient had developed an antinucleocapsid antibody response comparable to that of other immunocompetent severe COVID-19 subjects, both in magnitude and kinetics (Fig. 2B ). In contrast, the serum antispike antibody titer remained below the detection level throughout his clinical course (Fig. 2B) . Thus, the viral clearance was significantly delayed, and the level of RNAemia in the patient remained persistently high, while that of the other immunocompetent COVID-19 subjects gradually declined as their illness subsided (Fig. 2C) . On day 29 of illness, the patient unfortunately died due to poor oxygenation despite maximized ventilator mechanics. The patient's clinical course is summarized in Figure 3 . The majority of patients receiving anti-CD20 B-celltargeted therapies still successfully clear the virus, resulting in a mere self-limited infection, although some have reported severe respiratory distress or even fatal COVID-19 disease in patients treated with rituximab or ocrelizumab (5), resembling the case presented here. Irrespective of the clinical course or severity, however, this specific population seems to suffer a suboptimal SARS-CoV-2 antibody response (2) (3) (4) . Through detailed molecular and serological analyses, we investigated whether or not a B-cell-depleted patient could develop significant levels of antibodies targeting variable viral antigens. Our results revealed not a mere attenuation but a unique discrepancy in antigen-specific antibody responses. His persistent RNAemia and fatal phenotype were associated with a below-detection anti-spike antibody titer and negligible in vitro viral neutralizability despite an anti-nucleocapsid antibody response comparable to that of other immunocompetent COVID-19 subjects. One explanation for the specifically attenuated anti-spike IgG response may be that it reflects the differences in immunogenicity between the two antigens, with the spike antigen harboring less immunogenicity than the nucleocapsid antigen. A similar heterogenous attenuation in antibody response has been observed in the strain-or serotype-specific antibody responses to influenza and pneumococcal vaccines (8) . These facts raise concerns that the immunogenicity of the first generation of COVID-19 vaccines targeting the whole spike antigen may fall short of effective protection. Regarding the treatment of an immunosuppressed population possessing low-level neutralization antibodies, since the report of the initial experience with convalescent plasma therapy for B-cell-ablated severe COVID-19 patients (9) , an increasing number of case series and one recently published retrospective matched-control study have now provided evidence suggesting its clinical benefit (10, 11) . The boost in neutralizability following convalescent plasma transfusion is thought to dampen the viral replication at an earlier stage, thus leading to mortality benefit. For this reason, convalescent plasma therapy and, more recently, monoclonal antibody therapies, namely casirivimab-imdevimab and sotrovi- mab, have now been approved for emergency usage by the U.S. Food and Drug Administration, with special emphasis placed on the targeting of patients with impaired humoral immunity (12) (13) (14) . While the benefits of early casirivimabimdevimab therapy for the prevention of severe COVID-19 have been demonstrated in a phase 3 trial (15), an anecdotal case report now indicates its potential use as a later treatment option, especially when B-cell-depleted patients are targeted (16) . Although the clinical consequences of a suboptimal SARS-CoV-2 antibody response warrant further investigation, the evidence altogether support the notion that humoral immunity plays the central role in SARS-CoV-2 clearance and prevention. Our observations indicate that B-cell-depleted patients on anti-CD20 therapy are not only excellent candidates for convalescent plasma, as well as the other forms of antibody therapy, but also an at-risk population meriting close monitoring for reinfection and post-vaccination responses. Analyses were conducted in accordance with the principles of the Declaration of Helsinki. The work was approved by the institutional ethics committee. Consent for publication was obtained from the patient's family. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma Negative SARS-CoV-2 antibody testing following COVID-19 infection in two MS patients treated with ocrelizumab Beyond COVID-19: DO MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies? COVID-19 vaccinereadiness for anti-CD20-depleting therapy in autoimmune diseases A serological assay to detect SARS-CoV-2 seroconversion in humans A neutralizing human antibody binds to the N-terminal domain of the spike protein of SARS-CoV-2 Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VE-LOCE study Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies Fundación INFANT-COVID-19 Group. Early high-titer plasma therapy to prevent severe covid-19 in older adults Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 Fact sheet for health care providers -emergency use authorization (EUA) of COVID-19 convalescent plasma for treatment of hospitalized patients with COVID-19 Fact sheet for health care providers -emergency use authorization (EUA) of REGEN-COV (casirivimab with imdevimab Fact sheet for health care providers -emergency use authorization (EUA) of sotrovimab Subcutaneous REGEN-COV antibody combination for COVID-19 prevention. medRxiv. Forthcoming Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: a tailored approach The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license ELISA data was acquired at the Research Support Platform, Graduate School of Medicine, Osaka City University. Serological tests were provided by Mokobio Biotechnology R&D, USA, and Abbott Japan, Japan.Teruhito Takakuwa and Yu Nakagama equally contributed to this work.